Blood metric ‘may predict survival’ in NSCLC brain metastases
The ratio of neutophils to lymphocytes can reduce the efficacy of steroids in patients on checkpoint inhibitors, researchers say
In patients with non-small cell lung cancer brain metastases treated with immune-checkpoint inhibitors and upfront steroids, a low neutrophil-to-lymphocyte ratio may predict worse overall survival, US oncologists say.
Published in Scientific Reports, the team retrospectively investigated overall survival and intracranial progression-free survival in 171 patients with non-small cell lung cancer (NSCLC) with brain metastases treated with checkpoint inhibitors.
